ICICI Prudential Nifty Pharma Index Fund Direct IDCW NAV today
AMFI: 150928ISIN: INF109KC12M7MUTF_IN: ICIC_PRU_NFTY_22GFFEICICI Prudential Mutual FundIndex funds
NAV ₹19.6106
NAV for 23 Oct 2026. Declared once a day.
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month.
- ₹163 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it.
- 0.51%15 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought.
- None
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot make the fund look cheap. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted.
- 37.030 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures.
- 2030 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer.
- 14 Dec 2022
ICICI Prudential Nifty Pharma Index Fund returns
Read from the direct plan's growth option: an IDCW plan's NAV falls by every payout, so it carries no return of its own
Over each window to 23 Oct 2026
| Over | ReturnTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. |
|---|---|---|
| 1 week | −1.76% | −1.75% |
| 1 month | −6.74% | −6.71% |
| 3 months | −1.27% | −1.17% |
| 6 months | +10.32% | +10.59% |
| 1 year | +12.79% | +13.35% |
| 3 years | +19.37% | +20.09% |
| 5 years | Needs 5 years | – |
₹10,000 put in on 15 Dec 2022 is ₹19,723 at the NAV of 23 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load.Over a year and longer, a return is the yearly rate. Benchmark: Nifty Pharma TRI, over the same days as the fund.
At the month end, 30 Sep 2026
| Over | FundTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer. |
|---|---|---|
| 1 year | +23.37% | +23.98% |
| 3 years | +19.70% | +20.43% |
| Since launch | +20.77% | +21.74% |
Benchmark: Nifty Pharma TRI. Both as the fund house states them for the month.
Return in each calendar year
- Fund, Direct GrowthCalendar year return. The change in NAV from the last NAV of one year to the last NAV of the next.
- Nifty Pharma TRIBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer.
- Loss
Highest year to Dec 2024, +38.8%; lowest year to Dec 2025, −2.6%Above the benchmark in 0 of 3 years
ICICI Prudential Nifty Pharma Index Fund SIP returns
₹10,000 on the 1st of every month, valued at the NAV of 23 Oct 2026
| Period | InvestedAmount invested. ₹10,000 on the 1st of every month, or the next day the fund priced, added up over the period. | Value todayValue today. What the units bought by every instalment are worth at the latest NAV. | Invested against value today | SIP returnSIP return (XIRR). The yearly rate that, applied to each monthly instalment from the day it was invested, gives the value of all the units today. | After stamp dutySIP return after stamp duty. The same SIP return with stamp duty of 0.005% taken from every instalment since 1 Jul 2020, so ₹10,000 buys ₹9,999.50 of units. | Stamp dutyStamp duty paid. The stamp duty on all the instalments, in rupees: 0.005% of each purchase made since 1 Jul 2020. |
|---|---|---|---|---|---|---|
| 1 year12 instalments | ₹1,20,000 | ₹1,27,855₹1,27,849 after stamp duty | +12.92% | +12.91% | ₹6 | |
| 3 years36 instalments | ₹3,60,000 | ₹4,30,423₹4,30,402 after stamp duty | +12.13% | +12.13% | ₹18 | |
| Since Dec 202246 instalments | ₹4,60,000 | ₹6,22,134₹6,22,103 after stamp duty | +16.07% | +16.07% | ₹23 |
5 years: Launched 14 Dec 2022, needs 5 years of history.
From the Direct Growth plan's NAV, since an IDCW plan's NAV falls by each payout.
Rolling returns
Per cent a year, every window from 15 Dec 2022 to 23 Oct 2026
Lowest to highestAverage
LowestLowest rolling return. The worst yearly return of any window of this length in the fund's history, one window starting on each day it priced.AverageAverage rolling return. The average of the yearly returns of every window of this length in the fund's history.HighestHighest rolling return. The best yearly return of any window of this length in the fund's history.Ended higherWindows that ended higher. The share of all the windows of this length in which the NAV ended above where it started.
1 year704 windows−8.4%+23.3%+62.7%90.2%
3 yearsLaunched 14 Dec 2022, needs 4 years of history
From the Direct Growth plan's NAV, since an IDCW plan's NAV falls by each payout.
Tracking error
Against Nifty Pharma TRI, as on 30 Sep 2026.
Against its index, by window
| Measure | Direct, this plan | Regular |
|---|---|---|
| Tracking errorTracking error. How much an index fund's daily returns differed from its index's, stated as a yearly figure. | 0.05% | 0.06% |
| Difference, 1 yearTracking difference. The index fund's return less its index's return over the same period; the fund's costs make it negative. | −0.60 pts | −1.40 pts |
| Difference, 3 years | −0.74 pts | −1.48 pts |
| Difference since launch | −0.97 pts | −1.74 pts |
Difference: the fund's return less the index's, in percentage points.
ICICI Prudential Nifty Pharma Index Fund expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- Regular over directDirect and regular plan cost gap. The regular plan's expense ratio less the direct plan's: what buying through a distributor costs each year, since both plans own the same portfolio.
- 0.67 ptsA year, on 15 Oct 2026
- Direct, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies.
- 0.51%Over the last 30 days filed
- Regular, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies.
- 1.18%Over the last 30 days filed
Total expense ratio, month by month
- Regular plan
- Direct plan
Direct plan highest 0.52%, Aug 2026.Direct plan lowest 0.29%, Mar 2024.
What the expense ratio is made of
| Part | Direct | Regular |
|---|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. | 0.32% | 0.89% |
| Brokerage | 0.01% | 0.01% |
| Transaction costs | None | None |
| Statutory levies | 0.18% | 0.28% |
Per cent of assets a year, filed for 15 Oct 2026. The parts add up to that day's total.
Buying and selling
- Lump-sum purchases
- Not accepted
- Minimum investmentMinimum investment. The smallest amount the plan accepts for a first purchase.
- ₹1,000
- Minimum top-up
- ₹1,000
- Minimum redemption
- ₹1
- SIP
- Not accepted
- STP, transfers to another fund
- Not accepted
- SWP, regular withdrawals
- Not accepted
- Switches
- Accepted
- Lock-inLock-in. The time after each purchase during which those units cannot be sold.
- None
- SIP minimum
- Daily,Weekly,Fortnightly,Monthly = Rs. 1000Quarterly = Rs. 5,000
- SIP instalments, at least
- Daily,Weekly,Fortnightly,Monthly = 6Quarterly = 4
- SIP dates
- Daily = Daily (only business days)Weekly = Anyday (Monday to Friday)*Fortnightly = 1st and 16th day of each month as applicableMonthly = Any date*Quarterly = Any date**In case the date chosen for SIP falls on a Non-Business Day or on a date which is not available in a particular month, the SIP will beprocessed on the immediate next Business Day.
As listed for this plan on 24 Oct 2026.
ICICI Prudential Nifty Pharma Index Fund AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹151 CrQuarter to Sep 2026
- In the direct plansShare of assets in the direct plans. The direct plans' average assets for the quarter as a percentage of the fund's total; the rest is in the regular plans, bought through distributors.
- 69.2%Of the quarter's average
Average assets by quarter, by plan
- Regular plans
- Direct plans
The latest quarter is the largest since the quarter to Jun 2022.
Assets at each month end
The latest month end is the highest since Dec 2023.Lowest ₹28 Cr, Dec 2023.
ICICI Prudential Nifty Pharma Index Fund portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. | |||
|---|---|---|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 19.50% | 31.81 | 1,75,082 | Dec 2022or earlier |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 11.97% | 19.52 | 21,013 | Dec 2022or earlier |
| Laurus LabsPharmaceuticals & Biotechnology | Mid cap171st | 7.82% | 12.75 | 64,400 | Dec 2022or earlier |
| CiplaPharmaceuticals & Biotechnology | Large cap99th | 7.68% | 12.52 | 93,053 | Dec 2022or earlier |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | Mid cap104th | 7.62% | 12.43 | 1,00,842 | Dec 2022or earlier |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Large cap61st | 7.16% | 11.68 | 24,332 | Dec 2022or earlier |
| LupinPharmaceuticals & Biotechnology | Mid cap105th | 5.00% | 8.15 | 40,165 | Dec 2022or earlier |
| Aurobindo PharmaPharmaceuticals & Biotechnology | Mid cap138th | 4.68% | 7.64 | 45,698 | Dec 2022or earlier |
| Glenmark PharmaceuticalsPharmaceuticals & Biotechnology | Mid cap176th | 3.56% | 5.81 | 24,895 | Dec 2022or earlier |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | Mid cap164th | 3.16% | 5.15 | 9,970 | Dec 2022or earlier |
| Zydus LifesciencesPharmaceuticals & Biotechnology | Mid cap114th | 2.92% | 4.76 | 40,975 | Dec 2022or earlier |
| Mankind PharmaPharmaceuticals & Biotechnology | Mid cap119th | 2.88% | 4.69 | 18,737 | Mar 2024 |
| IPCA LaboratoriesPharmaceuticals & Biotechnology | Mid cap229th | 2.71% | 4.43 | 22,971 | Dec 2022or earlier |
| BioconPharmaceuticals & Biotechnology | Mid cap173rd | 2.62% | 4.27 | 1,15,240 | Dec 2022or earlier |
| Gland PharmaPharmaceuticals & Biotechnology | Small cap261st | 2.34% | 3.82 | 13,178 | Dec 2022or earlier |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | ||
|---|---|---|
| TREPS | 1.50% | 2.45 |
| Net Current Assets | −1.44% | −2.35 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions.
- 19.50%Sun Pharmaceutical Industries
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions.
- 54.59%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions.
- 78.16%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights.
- 11.4Taken over 99.94% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought.- Indian shares99.94%
- Cash and receivables0.06%
Per cent of the fund's net assets.
Large, mid and small cap
Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month.- Large cap46.34%
- Mid cap46.10%
- Small cap7.56%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets.1sector
- Healthcare99.94%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026.
Sector allocation month by month
| 13 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare20 companies | 99.94% | 99.93% | 99.96% | 99.94% | 99.50% | 99.94% | 99.86% | 99.35% | 100.35% | 99.95% | 99.97% | 99.98% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before.
- 0
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date.
- 0
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth.
- 20
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth.
- 0
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price.
- 0
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month.
- 0.00%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it.
- 2.28%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. | ||||
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Added | 19.50% | 20.76% | −1.26 pts | +10,976 |
| Dr. Reddy's Laboratories | Added | 7.62% | 6.95% | +0.67 pts | +6,371 |
| Laurus Labs | Added | 7.82% | 7.36% | +0.46 pts | +4,108 |
| Biocon | Added | 2.62% | 2.90% | −0.29 pts | +4,670 |
| Lupin | Added | 5.00% | 5.25% | −0.25 pts | +2,534 |
| Wockhardt | Added | 1.77% | 1.54% | +0.24 pts | +871 |
| Ajanta Pharma | Added | 1.67% | 1.50% | +0.18 pts | +1,021 |
| Torrent Pharmaceuticals | Added | 7.16% | 7.34% | −0.18 pts | +1,608 |
| Mankind Pharma | Added | 2.88% | 2.70% | +0.17 pts | +1,203 |
| Cipla | Added | 7.68% | 7.83% | −0.15 pts | +5,853 |
| Sai Life Sciences | Added | 2.14% | 1.99% | +0.15 pts | +1,496 |
| Glenmark Pharmaceuticals | Added | 3.56% | 3.69% | −0.12 pts | +1,570 |
| Abbott India | Added | 1.43% | 1.31% | +0.12 pts | +66 |
| Divi's Laboratories | Added | 11.97% | 11.88% | +0.09 pts | +1,325 |
| Alkem Laboratories | Added | 3.16% | 3.08% | +0.08 pts | +914 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points.
Holdings month by month
| Holding | Oct 25 | Nov 25 | Dec 25 | Jan 26 | Feb 26 | Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries | 22.18%Cut | 23.17%Cut | 22.05%Added | 21.38%Added | 21.81%Cut | 22.89%Added | 22.53%Added | 21.33%Added | 21.31%Added | 21.33%Added | 20.76%Added | 19.50%Added |
 Divi's Laboratories | 10.66%Cut | 9.87%Cut | 9.84%Added | 9.73%Added | 9.65%Cut | 9.30%Added | 9.72%Added | 9.48%Added | 9.04%Added | 10.36%Added | 11.88%Added | 11.97%Added |
 Laurus Labs | 4.61%Cut | 4.81%Cut | 5.21%Added | 4.75%Added | 4.96%Cut | 4.75%Added | 5.04%Added | 5.93%Added | 6.38%Added | 7.15%Added | 7.36%Added | 7.82%Added |
 Cipla | 10.51%Cut | 10.34%Cut | 10.30%Added | 9.43%Added | 8.99%Cut | 8.47%Added | 8.67%Added | 8.83%Added | 8.91%Added | 8.39%Added | 7.83%Added | 7.68%Added |
 Dr. Reddy's Laboratories | 9.08%Cut | 9.20%Cut | 9.38%Added | 9.40%Added | 9.29%Cut | 9.41%Added | 9.49%Added | 8.89%Added | 8.94%Added | 7.08%Added | 6.95%Added | 7.62%Added |
 Torrent Pharmaceuticals | 4.64%Cut | 4.67%Cut | 4.88%Added | 5.24%Added | 5.37%Cut | 5.43%Added | 5.15%Added | 5.16%Added | 5.24%Added | 7.60%Added | 7.34%Added | 7.16%Added |
 Lupin | 5.91%Cut | 6.05%Cut | 6.19%Added | 6.61%Added | 6.62%Cut | 6.90%Added | 6.58%Added | 6.16%Added | 6.35%Added | 5.94%Added | 5.25%Added | 5.00%Added |
 Aurobindo Pharma | 3.97%Cut | 4.12%Cut | 4.01%Added | 4.28%Added | 4.05%Cut | 4.49%Added | 4.57%Added | 4.46%Added | 4.72%Cut | 4.43%Added | 4.69%Added | 4.68%Added |
 Glenmark Pharmaceuticals | 3.55%Cut | 3.52%Cut | 3.71%Added | 3.84%Added | 3.81%Cut | 3.95%Added | 4.26%Added | 3.83%Added | 3.59%Added | 3.40%Added | 3.69%Added | 3.56%Added |
 Alkem Laboratories | 3.86%Cut | 3.84%Cut | 3.90%Added | 4.21%Added | 3.91%Cut | 3.81%Added | 3.72%Added | 3.60%Added | 3.52%Added | 3.40%Added | 3.08%Added | 3.16%Added |
 Zydus Lifesciences | 3.03%Cut | 2.83%Cut | 2.77%Added | 2.80%Added | 2.73%Cut | 2.68%Added | 2.63%Added | 3.02%Added | 3.01%Added | 2.85%Added | 2.87%Added | 2.92%Added |
 Mankind Pharma | 3.36%Cut | 3.05%Cut | 3.01%Added | 3.04%Added | 3.01%Cut | 2.79%Added | 2.99%Added | 3.01%Added | 3.12%Added | 2.83%Added | 2.70%Added | 2.88%Added |
 IPCA Laboratories | 2.20%Cut | 2.42%Cut | 2.39%Added | 2.59%Added | 2.52%Cut | 2.74%Added | 2.50%Added | 2.37%Added | 2.55%Added | 2.46%Added | 2.71%Added | 2.71%Added |
 Biocon | 2.78%Cut | 2.87%Cut | 2.86%Added | 3.31%Added | 3.30%Cut | 3.17%Added | 3.02%Added | 3.43%Added | 3.23%Added | 3.07%Added | 2.90%Added | 2.62%Added |
 Gland Pharma | 1.91%Cut | 1.68%Cut | 1.66%Added | 1.86%Added | 1.72%Cut | 1.66%Added | 1.64%Added | 2.00%Added | 2.15%Added | 2.02%Added | 2.27%Added | 2.34%Added |
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.
Portfolio turnover, per cent of assets a year
- TurnoverPortfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it.
Highest 32.0% in Jul 2026
Risk ratios
NAV to 23 Oct 2026
How much the NAV moves
Standard deviationStandard deviation. How far the fund's monthly returns spread around their average, stated as a yearly figure: the wider the spread, the more the NAV moves.16.17%
Downside deviationDownside deviation. Standard deviation counting only the months in which the fund lost money, stated as a yearly figure.8.75%
Sharpe ratioSharpe ratio. The monthly return above the 91-day Treasury bill yield, divided by its standard deviation and stated for a year: the extra return for each unit of movement in the NAV.0.84
Sortino ratioSortino ratio. The monthly return above the 91-day Treasury bill yield, divided by how far it fell below that yield and stated for a year: the extra return for each unit of movement on the way down.1.40
From the Direct Growth plan's NAV, since an IDCW plan's NAV falls by each payout.
Against Nifty Pharma TRI
BetaBeta. How much the fund's monthly return moved for each 1% move in its benchmark: 1 moves with it, below 1 moves less.1.00
AlphaAlpha. The yearly return the fund made beyond what its beta to the benchmark accounts for.−0.70 pts
R-squaredR-squared. The share of the fund's monthly movement that its benchmark's movement explains, from 0 to 100.100.0
CorrelationCorrelation. How closely the fund's monthly returns moved in step with its benchmark's, from minus 1 (always opposite) to 1 (always together).1.00
Upside captureUpside capture. The fund's return in the months its benchmark rose, as a percentage of the benchmark's return in those months.98.8%
Downside captureDownside capture. The fund's return in the months its benchmark fell, as a percentage of the benchmark's fall in those months.101.5%
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. |
|---|---|---|---|---|
| 1 year | −7.49% | 7 Jan 2026 | 2 Feb 2026 | 26 Feb 2026 |
| 3 years and since Dec 2022 | −16.59% | 9 Oct 2024 | 28 Feb 2025 | 6 May 2026 |
Risk level by month
| Months | FundRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. |
|---|---|---|
| Mar 2025 to Aug 202618 months | Very High | Very HighNifty Pharma TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
ICICI Prudential Nifty Pharma Index Fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. | ||
|---|---|---|---|---|---|---|---|---|
| Nishit PatelComanage | Dec 2022 | +19.91%a year | +20.86% | −0.95 pts | – | – | 60 | ₹1,98,042 Cr |
| Ashwini BharuchaComanage | Dec 2024 | +8.53%a year | +8.99% | −0.46 pts | 2.3% | 5.2% | 49 | ₹1,78,831 Cr |
| Venus Ahuja | Nov 2025 | +15.03%over 347 days | +15.56% | −0.53 pts | 4.0% | 4.6% | 58 | ₹2,00,156 Cr |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Other funds they run
| Fund | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. | ||
|---|---|---|---|---|---|
| ICICI Prudential Nifty 50 ETFNishit Patel | Jan 2021 | – | +10.08% | – | ₹42,735 Cr |
| ICICI Prudential BSE Sensex ETFNishit Patel | Jan 2021 | – | – | – | ₹31,610 Cr |
| ICICI Prudential Gold ETFNishit Patel | Dec 2024 | – | – | – | ₹27,615 Cr |
| ICICI Prudential Nifty 50 Index FundNishit Patel | Jan 2021 | +9.79%a year | +10.08% | −0.29 pts | ₹16,311 Cr |
| ICICI Prudential Silver ETFNishit Patel | Dec 2024 | – | – | – | ₹14,341 Cr |
| ICICI Prudential Nifty Next 50 Index FundNishit Patel | Jan 2021 | +13.99%a year | +14.56% | −0.57 pts | ₹9,744 Cr |
| Bharat 22 ETFNishit Patel | Nov 2017 | – | – | – | ₹9,531 Cr |
| ICICI Prudential Gold ETF FOFNishit Patel | Dec 2020 | +19.52%a year | – | – | ₹7,067 Cr |
| ICICI Prudential Silver ETF FOFNishit Patel | Feb 2022 | +28.01%a year | – | – | ₹6,180 Cr |
| ICICI Prudential Nifty Private Bank ETFNishit Patel | Jan 2021 | – | – | – | ₹4,179 Cr |
Up to ten funds a manager, largest first. Returns are the direct plan's.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. | Shared holdings. The number of securities both funds hold, cash and futures left out. | |
|---|---|---|
| DSP Nifty Healthcare Index FundDSP Mutual Fund | 81.15% | 16 |
| Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 61.20% | 20 |
| Edelweiss Msci India Domestic & World Healthcare 45 Index FundEdelweiss Mutual Fund | 53.09% | 17 |
| Motilal Oswal Nifty MidSmall Healthcare Index FundMotilal Oswal Mutual Fund | 43.09% | 14 |
| Tata Nifty MidSmall Healthcare Index FundTata Mutual Fund | 43.09% | 14 |
| Tata Nifty500 Multicap India Manufacturing 50 30 20 Index FundTata Mutual Fund | 21.30% | 14 |
| Nippon India Nifty 500 Low Volatility 50 Index FundNippon India Mutual Fund | 19.29% | 7 |
| Nippon India Nifty India Manufacturing IndexNippon India Mutual Fund | 18.29% | 10 |
| Navi Nifty India Manufacturing Index FundNavi Mutual Fund | 18.25% | 10 |
| Motilal Oswal BSE Midcap 150 Momentum 30 Index FundMotilal Oswal Mutual Fund | 15.90% | 5 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
Fund details
Objective
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Asset allocation
- Equity and Equity related securities of companies constituting the underlying index (Nifty Pharma Index) = 95% - 100%
- Money Market instruments including TREPs* and Units of debt schemes# = 0% - 5%
Type of scheme
Open Ended
- Stated category
- Other Schemes – Index Fund
- BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back.
- Nifty Pharma TRI
- Risk level at launchRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very High
- New fund offer
- 25 Nov 2022 to 9 Dec 2022
- Units first allotted
- 14 Dec 2022
- Open for sale again
- 19 Dec 2022
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹1,000
Plans and codes
| Plan | AMFI code | ISIN | ISIN, reinvestment | MUTF_IN | First NAV |
|---|---|---|---|---|---|
| Direct Growth | 150930 | INF109KC11M9 | ICIC_PRU_NFTY_4NHDKJ | 15 Dec 2022 | |
| Regular Growth | 150929 | INF109KC18L6 | ICIC_PRU_NFTY_LAU114 | 15 Dec 2022 | |
| Direct IDCW | 150928 | INF109KC12M7 | INF109KC13M5 | ICIC_PRU_NFTY_22GFFE | 15 Dec 2022 |
| Regular IDCW | 150931 | INF109KC19L4 | INF109KC10M1 | ICIC_PRU_NFTY_14KKN9 | 15 Dec 2022 |
This fund
- Scheme information document (opens in a new tab)The fund's objective, terms, costs and risks in full
Factsheet
- Complete Factsheet September 2026 (opens in a new tab)ICICI Prudential Mutual Fund, Sep 2026
- Passive Fund Factsheet September 2026 (opens in a new tab)ICICI Prudential Mutual Fund, Sep 2026
Statement of additional information
- SAI ICICI Prudential Mutual Fund (opens in a new tab)ICICI Prudential Mutual Fund, Oct 2026
Annual report
- ICICI Prudential All Seasons Bond Fund (opens in a new tab)ICICI Prudential Mutual Fund, Mar 2026
- ICICI Prudential Banking and Financial Services Fund (opens in a new tab)ICICI Prudential Mutual Fund, Mar 2026
- ICICI Prudential Banking and PSU Debt Fund (opens in a new tab)ICICI Prudential Mutual Fund, Mar 2026
- ICICI Prudential Balanced Advantage Fund (opens in a new tab)ICICI Prudential Mutual Fund, Mar 2026
Riskometer disclosure
- Annual Disclosure of Scheme Riskometer FY 2025-26 (opens in a new tab)ICICI Prudential Mutual Fund, Mar 2026
Portfolio overlap disclosure
- Portfolio Overlap September 2026 (opens in a new tab)ICICI Prudential Mutual Fund, Sep 2026